Please assess the completion status of the following clinical trial:

Trial Title: Resveratrol in Type2 Diabetes and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 20 years of age and older~2. Healthy Obese subjects with BMI \> 30~3. Type 2 Diabetics with BMI \> 30~4. Subjects with good peripheral vein.~5. Subjects on statins, ACE inhibitors and thiazolidenediones will be allowed as long as they are on stable doses of these compounds and the dosage is not changed during the course of study.~Exclusion Criteria:~1. Subjects on any antioxidant medication~2. Patient on non-steroidal anti-inflammatory drug~3. On any agent with significant antioxidant properties.~4. History of drug or alcohol abuse~5. Any life threatening disease~6. Allergy to peanuts, grapes, wine, mulberries.~7. Pregnant women.~8. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks.~9. Subjects on anticoagulants.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets
- Resveratrol 40 mg oral three times a day (Type: EXPERIMENTAL): Resveratrol
- resveratrol 500 mg oral once daily. (Type: EXPERIMENTAL): Resveratrol

Based on this trial design, predict the completion outcome and termination type (if applicable).